FDA Adverse Event Injury Summary report: N

EMERGE?

MDR report key: 21454161 · Received February 24, 2025

Report

Report Number
2124215-2025-10341
Event Type
Injury
Date Received
February 24, 2025
Date of Event
February 3, 2025
Report Date
April 8, 2026
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
LOX
UDI-DI
08714729806257
PMA / PMN Number
K113220
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
OH, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

G4: PREMARKET / 510(K): K163174.

Additional Manufacturer Narrative · 0

G4: PREMARKET / 510(K): K163174.

Additional Manufacturer Narrative · 0

CORRECTION: H6 PATIENT CODES. THIS REPORT WAS AMENDED TO UPDATE INTERNATIONAL MEDICAL DEVICE REGULATORS FORUM (IMDRF) CODES. INCOMPLETE CODING OF THIS EVENT WAS IDENTIFIED DURING A RETROSPECTIVE REVIEW OF COMPLAINTS ASSOCIATED WITH CAPA-8580, WHICH FOCUSED ON IDENTIFYING AND REMEDIATING INCOMPLETE CODING OF EVENTS. DEVICE ANALYSIS RESULTS: DEVICE TECHNICAL ANALYSIS: THE DEVICE WAS NOT RETURNED FOR ANALYSIS; THEREFORE, A TECHNICAL ANALYSIS COULD NOT BE PERFORMED. DEVICE HISTORY REVIEW: IT WAS CONFIRMED THAT THIS DEVICE MET MANUFACTURING SPECIFICATION PRIOR TO DISTRIBUTION AND THERE ARE NO MANUFACTURING DEVIATIONS WHICH COULD HAVE CONTRIBUTED TO THE REPORTED EVENT. LABELING REVIEW: REVIEW OF THE INSTRUCTIONS FOR USE (IFU) CONFIRMED THERE WAS RELEVANT CONTENT AND SUFFICIENT GUIDANCE WITH RESPECT TO THE CIRCUMSTANCES DESCRIBED WITHIN THIS COMPLAINT. NO UPDATES ARE REQUIRED TO THE IFU AS A RESULT OF THIS EVENT. BASED ON THE AVAILABLE INFORMATION, THERE WAS NO EVIDENCE OF DEVICE OFF-LABEL USE, OR FAILURE TO FOLLOW THE INSTRUCTIONS FOR USE (IFU). RISK REVIEW: A RISK REVIEW WAS PERFORMED, AND IT CONFIRMED THAT THE EVENT WAS DEFINED IN THE RISK DOCUMENTATION. THIS EVENT TYPE HAS BEEN ACCOUNTED FOR DURING PRODUCT RISK ANALYSIS TO SUPPORT ACCEPTABLE RISK BENEFIT FOR THE PRODUCT. INVESTIGATION CONCLUSION: THE CONCLUSION CODE OF ADVERSE EVENT RELATED TO PROCEDURE WAS SELECTED. THIS CODE WAS SELECTED AS THE MOST PROBABLE COMPLAINT CAUSE BASED ON THE INFORMATION AVAILABLE. THE REPORTED EVENT COULD NOT BE CONFIRMED AS THE DEVICE WAS NOT RETURNED FOR ANALYSIS. BASED ON THE EVENT DESCRIPTION THE REPORTED SHAFT BREAK WAS MOST LIKELY RELATED TO A COMBINATION OF PROCEDURAL FACTORS. THESE WOULD INCLUDE INTERACTIONS OF THE DEVICE WITH OTHER ANCILLARY DEVICES USED, AS WELL AS INTERACTIONS WITH ANATOMICAL FACTORS SUCH AS CALCIFICATION OR TORTUOSITY DURING THE PROCEDURE. THE SHAFT BREAK LED TO THE VESSEL OCCLUSION (INCLUDING SIDE BRANCH AND TOTAL VESSEL OCCLUSION) AND EMBOLISM WHICH ARE KNOWN INHERENT RISKS OF THE DEVICE AND ARE LISTED IN THE INSTRUCTIONS FOR USE. G4: PREMARKET / 510(K): K163174.

Description of Event or Problem · 0

IT WAS REPORTED THAT A DEVICE ISSUE OCCURRED RESULTING IN PATIENT COMPLICATIONS. THE GREATER THAN 90% STENOSED TARGET LESION WAS LOCATED IN A MILDLY TORTUOUS AND MODERATELY TO SEVERELY CALCIFIED CORONARY ARTERY. A 3.50MM X 15MM NC EMERGE BALLOON CATHETER WAS ADVANCED THROUGH THE SAPHENOUS VEIN GRAFT (SVG) TO TREAT CORONARY ARTERY DISEASE (CAD). HOWEVER, UPON REMOVAL OF THE BALLOON AFTER INFLATION, THE DISTAL HALF OF THE BALLOON AND THE DISTAL CATHETER TIP DETACHED AND BECAME LODGED INSIDE THE VESSEL. THE PATIENT EXPERIENCED VESSEL OCCLUSION DUE TO THE BROKEN BALLOON REMAINING IN THE VESSEL. ATTEMPTS WERE MADE TO SNARE AND TRAP THE BALLOON WITH ANOTHER BALLOON, HOWEVER, THE DETACHED PIECE FLOATED OUT OF THE SVG INTO THE AORTIC CIRCULATION. THE PROCEDURE WAS NOT COMPLETED DUE TO VESSEL CLOSURE AND PATIENT INSTABILITY. PHARMACOLOGICAL AGENTS WERE ADMINISTERED TO LEAVE THE PATIENT IN A HEMODYNAMICALLY STABLE CONDITION.

Description of Event or Problem · 0

IT WAS REPORTED THAT A DEVICE ISSUE OCCURRED RESULTING IN-PATIENT COMPLICATIONS. THE GREATER THAN 90% STENOSED TARGET LESION WAS LOCATED IN A MILDLY TORTUOUS AND MODERATELY TO SEVERELY CALCIFIED CORONARY ARTERY. A 3.50MM X 15MM NC EMERGE BALLOON CATHETER WAS ADVANCED THROUGH THE SAPHENOUS VEIN GRAFT (SVG) TO TREAT CORONARY ARTERY DISEASE (CAD). HOWEVER, UPON REMOVAL OF THE BALLOON AFTER INFLATION, THE DISTAL HALF OF THE BALLOON AND THE DISTAL CATHETER TIP DETACHED AND BECAME LODGED INSIDE THE VESSEL. THE PATIENT EXPERIENCED VESSEL OCCLUSION DUE TO THE BROKEN BALLOON REMAINING IN THE VESSEL. ATTEMPTS WERE MADE TO SNARE AND TRAP THE BALLOON WITH ANOTHER BALLOON, HOWEVER, THE DETACHED PIECE FLOATED OUT OF THE SVG INTO THE AORTIC CIRCULATION. THE PROCEDURE WAS NOT COMPLETED DUE TO VESSEL CLOSURE AND PATIENT INSTABILITY. PHARMACOLOGICAL AGENTS WERE ADMINISTERED TO LEAVE THE PATIENT IN A HEMODYNAMICALLY STABLE CONDITION. IT WAS FURTHER REPORTED VIA MEDWATCH (B)(4) THAT THE FRAGMENT EMBOLIZED AND ENLARGED IN THE THORACIC ARTERY.

Description of Event or Problem · 0

IT WAS REPORTED THAT A DEVICE ISSUE OCCURRED RESULTING IN PATIENT COMPLICATIONS. THE GREATER THAN 90% STENOSED TARGET LESION WAS LOCATED IN A MILDLY TORTUOUS AND MODERATELY TO SEVERELY CALCIFIED CORONARY ARTERY. A 3.50MM X 15MM NC EMERGE BALLOON CATHETER WAS ADVANCED THROUGH THE SAPHENOUS VEIN GRAFT (SVG) TO TREAT CORONARY ARTERY DISEASE (CAD). HOWEVER, UPON REMOVAL OF THE BALLOON AFTER INFLATION, THE DISTAL HALF OF THE BALLOON AND THE DISTAL CATHETER TIP DETACHED AND BECAME LODGED INSIDE THE VESSEL. THE PATIENT EXPERIENCED VESSEL OCCLUSION DUE TO THE BROKEN BALLOON REMAINING IN THE VESSEL. ATTEMPTS WERE MADE TO SNARE AND TRAP THE BALLOON WITH ANOTHER BALLOON, HOWEVER, THE DETACHED PIECE FLOATED OUT OF THE SVG INTO THE AORTIC CIRCULATION. THE PROCEDURE WAS NOT COMPLETED DUE TO VESSEL CLOSURE AND PATIENT INSTABILITY. PHARMACOLOGICAL AGENTS WERE ADMINISTERED TO LEAVE THE PATIENT IN A HEMODYNAMICALLY STABLE CONDITION. IT WAS FURTHER REPORTED THAT THE FRAGMENT EMBOLIZED AND ENLARGED IN THE THORACIC ARTERY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
249736 EMERGE? CATHETERS, TRANSLUMINAL CORONARY ANGIOPLASTY, PERCUTANEOUS LOX BOSTON SCIENTIFIC CORPORATION H7493918915350 0033107028 08714729806257

Patients

Seq Age Sex Outcome Treatment
1